1. Home
  2. SLXN vs SLE Comparison

SLXN vs SLE Comparison

Compare SLXN & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • SLE
  • Stock Information
  • Founded
  • SLXN 2008
  • SLE 2014
  • Country
  • SLXN Israel
  • SLE United States
  • Employees
  • SLXN N/A
  • SLE N/A
  • Industry
  • SLXN
  • SLE Services-Misc. Amusement & Recreation
  • Sector
  • SLXN
  • SLE Consumer Discretionary
  • Exchange
  • SLXN NYSE
  • SLE Nasdaq
  • Market Cap
  • SLXN 6.9M
  • SLE 6.5M
  • IPO Year
  • SLXN N/A
  • SLE 2019
  • Fundamental
  • Price
  • SLXN $0.92
  • SLE $0.18
  • Analyst Decision
  • SLXN Strong Buy
  • SLE Strong Buy
  • Analyst Count
  • SLXN 1
  • SLE 2
  • Target Price
  • SLXN $5.00
  • SLE $2.50
  • AVG Volume (30 Days)
  • SLXN 3.6M
  • SLE 741.9K
  • Earning Date
  • SLXN 05-13-2025
  • SLE 05-15-2025
  • Dividend Yield
  • SLXN N/A
  • SLE N/A
  • EPS Growth
  • SLXN N/A
  • SLE N/A
  • EPS
  • SLXN N/A
  • SLE N/A
  • Revenue
  • SLXN N/A
  • SLE $16,181,999.00
  • Revenue This Year
  • SLXN N/A
  • SLE N/A
  • Revenue Next Year
  • SLXN N/A
  • SLE $38.58
  • P/E Ratio
  • SLXN N/A
  • SLE N/A
  • Revenue Growth
  • SLXN N/A
  • SLE N/A
  • 52 Week Low
  • SLXN $0.21
  • SLE $0.17
  • 52 Week High
  • SLXN $13.56
  • SLE $1.74
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • SLE 36.21
  • Support Level
  • SLXN N/A
  • SLE $0.15
  • Resistance Level
  • SLXN N/A
  • SLE $0.18
  • Average True Range (ATR)
  • SLXN 0.00
  • SLE 0.05
  • MACD
  • SLXN 0.00
  • SLE -0.02
  • Stochastic Oscillator
  • SLXN 0.00
  • SLE 12.26

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About SLE Super League Enterprise Inc.

Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.

Share on Social Networks: